493 related articles for article (PubMed ID: 26232335)
1. Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs.
Li MX; Hwang PM
Gene; 2015 Oct; 571(2):153-66. PubMed ID: 26232335
[TBL] [Abstract][Full Text] [Related]
2. The cardiac-specific N-terminal region of troponin I positions the regulatory domain of troponin C.
Hwang PM; Cai F; Pineda-Sanabria SE; Corson DC; Sykes BD
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14412-7. PubMed ID: 25246568
[TBL] [Abstract][Full Text] [Related]
3. Dilated Cardiomyopathy Mutations and Phosphorylation disrupt the Active Orientation of Cardiac Troponin C.
Mahmud Z; Dhami PS; Rans C; Liu PB; Hwang PM
J Mol Biol; 2021 Jun; 433(13):167010. PubMed ID: 33901537
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: influence of PKA phosphorylation and involvement in cardiomyopathies.
Baryshnikova OK; Li MX; Sykes BD
J Mol Biol; 2008 Jan; 375(3):735-51. PubMed ID: 18042489
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation and mutation of human cardiac troponin I deferentially destabilize the interaction of the functional regions of troponin I with troponin C.
Li MX; Wang X; Lindhout DA; Buscemi N; Van Eyk JE; Sykes BD
Biochemistry; 2003 Dec; 42(49):14460-8. PubMed ID: 14661957
[TBL] [Abstract][Full Text] [Related]
6. Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C.
Li MX; Spyracopoulos L; Sykes BD
Biochemistry; 1999 Jun; 38(26):8289-98. PubMed ID: 10387074
[TBL] [Abstract][Full Text] [Related]
7. The structure of cardiac troponin C regulatory domain with bound Cd2+ reveals a closed conformation and unique ion coordination.
Zhang XL; Tibbits GF; Paetzel M
Acta Crystallogr D Biol Crystallogr; 2013 May; 69(Pt 5):722-34. PubMed ID: 23633581
[TBL] [Abstract][Full Text] [Related]
8. Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.
Robertson IM; Baryshnikova OK; Li MX; Sykes BD
Biochemistry; 2008 Jul; 47(28):7485-95. PubMed ID: 18570382
[TBL] [Abstract][Full Text] [Related]
9. Mouse Models of Cardiomyopathies Caused by Mutations in Troponin C.
Tikunova SB; Thuma J; Davis JP
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569724
[TBL] [Abstract][Full Text] [Related]
10. Structures reveal details of small molecule binding to cardiac troponin.
Cai F; Li MX; Pineda-Sanabria SE; Gelozia S; Lindert S; West F; Sykes BD; Hwang PM
J Mol Cell Cardiol; 2016 Dec; 101():134-144. PubMed ID: 27825981
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive guide to genetic variants and post-translational modifications of cardiac troponin C.
Reinoso TR; Landim-Vieira M; Shi Y; Johnston JR; Chase PB; Parvatiyar MS; Landstrom AP; Pinto JR; Tadros HJ
J Muscle Res Cell Motil; 2021 Jun; 42(2):323-342. PubMed ID: 33179204
[TBL] [Abstract][Full Text] [Related]
12. Bepridil opens the regulatory N-terminal lobe of cardiac troponin C.
Li Y; Love ML; Putkey JA; Cohen C
Proc Natl Acad Sci U S A; 2000 May; 97(10):5140-5. PubMed ID: 10792039
[TBL] [Abstract][Full Text] [Related]
13. Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil.
Wang X; Li MX; Sykes BD
J Biol Chem; 2002 Aug; 277(34):31124-33. PubMed ID: 12060657
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of cardiac troponin C regulatory domain in complex with cadmium and deoxycholic acid reveals novel conformation.
Li AY; Lee J; Borek D; Otwinowski Z; Tibbits GF; Paetzel M
J Mol Biol; 2011 Oct; 413(3):699-711. PubMed ID: 21920370
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional consequences of the cardiac troponin C L48Q Ca(2+)-sensitizing mutation.
Wang D; Robertson IM; Li MX; McCully ME; Crane ML; Luo Z; Tu AY; Daggett V; Sykes BD; Regnier M
Biochemistry; 2012 Jun; 51(22):4473-87. PubMed ID: 22591429
[TBL] [Abstract][Full Text] [Related]
16. Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.
Pineda-Sanabria SE; Robertson IM; Sun YB; Irving M; Sykes BD
J Mol Cell Cardiol; 2016 Mar; 92():174-84. PubMed ID: 26853943
[TBL] [Abstract][Full Text] [Related]
17. Effects of T142 phosphorylation and mutation R145G on the interaction of the inhibitory region of human cardiac troponin I with the C-domain of human cardiac troponin C.
Lindhout DA; Li MX; Schieve D; Sykes BD
Biochemistry; 2002 Jun; 41(23):7267-74. PubMed ID: 12044157
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional impact of troponin C-mediated Ca
Gonzalez-Martinez D; Johnston JR; Landim-Vieira M; Ma W; Antipova O; Awan O; Irving TC; Bryant Chase P; Pinto JR
J Mol Cell Cardiol; 2018 Oct; 123():26-37. PubMed ID: 30138628
[TBL] [Abstract][Full Text] [Related]
19. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides.
Sorsa T; Pollesello P; Permi P; Drakenberg T; Kilpeläinen I
J Mol Cell Cardiol; 2003 Sep; 35(9):1055-61. PubMed ID: 12967628
[TBL] [Abstract][Full Text] [Related]
20. The Role of Electrostatics in the Mechanism of Cardiac Thin Filament Based Sensitizers.
Cai F; Robertson IM; Kampourakis T; Klein BA; Sykes BD
ACS Chem Biol; 2020 Aug; 15(8):2289-2298. PubMed ID: 32633482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
